Fractyl has the GUTS: Obesity and diabetes biotech charts $99M IPO
Fractyl Health is attempting to ride the waves created by last week’s successful biotech IPOs for cancer drugmakers CG Oncology and ArriVent Biopharma.
The cardiometabolic biotech said Monday morning it expects about $99 million in net proceeds from its Nasdaq debut, likely to occur later this week. That haul would come if the Massachusetts biotech prices at the midpoint of a proposed $14 to $16 range by selling 7.33 million shares as $GUTS.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.